Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for QMS Medical Allied Services's Debt-to-EBITDA or its related term are showing as below:
NSE:QMSMEDI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.16 Med: 1.84 Max: 2.77
Current: 2.58
During the past 7 years, the highest Debt-to-EBITDA Ratio of QMS Medical Allied Services was 2.77. The lowest was 1.16. And the median was 1.84.
NSE:QMSMEDI's Debt-to-EBITDA is ranked worse than 65.39% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs NSE:QMSMEDI: 2.58
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
QMS Medical Allied Services Debt-to-EBITDA Related Terms
QMS Medical Allied Services Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QMSMEDI vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, QMS Medical Allied Services's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QMS Medical Allied Services Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, QMS Medical Allied Services's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where QMS Medical Allied Services's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
QMS Medical Allied Services (NSE:QMSMEDI) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on QMS Medical Allied Services. Over the past decade, QMS Medical Allied Services' Debt-to-EBITDA has ranged from 1.16 to 2.77. According to the industry distribution chart, QMS Medical Allied Services ranks #308 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 65.4%.
Is QMS Medical Allied Services' Debt-to-EBITDA too high?
QMS Medical Allied Services' current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 1.16 to a high of 2.77. Based on the distribution chart, QMS Medical Allied Services ranks #308 out of 471 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, QMS Medical Allied Services has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does QMS Medical Allied Services' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, QMS Medical Allied Services ranks #308 out of 471 companies for Debt-to-EBITDA. This places QMS Medical Allied Services in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Historically, QMS Medical Allied Services' own Debt-to-EBITDA has ranged from 1.16 to 2.77 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on QMS Medical Allied Services. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QMS Medical Allied Services's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QMS Medical Allied Services stock overvalued right now?
Based on GuruFocus' analysis, QMS Medical Allied Services (NSE:QMSMEDI) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹130.26, compared to a current price of ₹155.17 — trading 19.1% above its estimated fair value. The current Debt-to-EBITDA is 0.00. QMS Medical Allied Services' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For QMS Medical Allied Services (NSE:QMSMEDI), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is QMS Medical Allied Services (NSE:QMSMEDI) Overvalued in 2026?
Based on GuruFocus' analysis, QMS Medical Allied Services stock appears to be overvalued.
The current stock price of ₹155.17 is trading 19.1% above its estimated GF Value™ of ₹130.26.
GuruFocus considers QMS Medical Allied Services to be Modestly Overvalued.
Key valuation signals for NSE:QMSMEDI:
Debt-to-EBITDA: 0.00
GF Value™: ₹130.26 vs. price of ₹155.17 (19.1% above fair value)
No single metric tells the full story. See the NSE:QMSMEDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
QMS Medical Allied Services Ltd is engaged in the marketing and distribution of a wide range of medical products as well as medical education services. The company's products are sold under brand name "QDevices" and also manage the distribution for other brands such as 3M, Heine, Rossmax and others. It offers medical products such as Blood Pressure Monitors, Glucose Monitoring Kits and strips, Dental Products, Personal protection kits eg-PPE kits, Infection prevention, Stethoscope and Oxygen Concentrator.
73GF Score
Get the complete analysis for NSE:QMSMEDI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QMSMEDI has been successfully added to your 
